title: Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach.
abstract: Historically, first-line treatment of non-small-cell lung cancer (NSCLC) has been based on giving a limited number of cycles of chemotherapy to achieve tumour response or stable disease. Patients are then observed without active therapy until disease progresses, at which point, subsequent lines of therapy are given. In recent years, two new concepts have been introduced to the management of NSCLC: maintenance therapy and therapy with targeted agents. Maintenance therapy-with either a chemotherapeutic or biologic agent-is given immediately after first-line therapy to patients who have achieved tumour response or stable disease. Choice of therapy may include continuation of the agents included in the induction regimen or introduction of different agents (early second-line treatment) with the aim of preventing progression and prolonging progression-free survival. Targeted agents such as bevacizumab and erlotinib target critical molecular signalling pathways and provide several advantages over chemotherapy, including fewer toxicities and the possibility of a longer duration of therapy. This review examines the treatment options in all lines of therapy for metastatic NSCLC, focusing particularly on targeted therapies that have been approved in the United States, Canada, or Europe.
authors.affiliation: Medical Oncology Department, MUHC Royal Victoria Hospital, Montreal, Quebec. vera.hirsh@muhc.mcgill.ca
authors.forename: V
authors.initials: V
authors.lastname: Hirsh
references.citation: Am J Pathol. 2004 Jul;165(1):35-52
references.pmid: 15215160
references.citation: Nat Rev Cancer. 2008 Aug;8(8):579-91
references.pmid: 18596824
references.citation: J Thorac Oncol. 2009 Nov;4(11 Suppl 3):S1071-3
references.pmid: 19861922
references.citation: Clin Lung Cancer. 2008 Mar;9 Suppl 2:S62-70
references.pmid: 21885001
references.citation: Science. 2005 Jan 7;307(5706):58-62
references.pmid: 15637262
references.citation: J Clin Oncol. 2004 Jun 1;22(11):2184-91
references.pmid: 15169807
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1227-34
references.pmid: 19188680
references.citation: J Clin Oncol. 2000 May;18(10):2095-103
references.pmid: 10811675
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3543-51
references.pmid: 18506025
references.citation: Cancer Control. 2001 Jul-Aug;8(4):326-36
references.pmid: 11483886
references.citation: Curr Oncol Rep. 2000 Jan;2(1):96-101
references.pmid: 11122830
references.citation: Clin Lung Cancer. 2009 Jul;10(4):252-6
references.pmid: 19632943
references.citation: J Thorac Oncol. 2009 Feb;4(2):243-50
references.pmid: 19179904
references.citation: N Engl J Med. 2009 Sep 3;361(10):947-57
references.pmid: 19692680
references.citation: J Clin Oncol. 2009 Jul 1;27(19):3217-24
references.pmid: 19433683
references.citation: N Engl J Med. 2005 Jul 14;353(2):123-32
references.pmid: 16014882
references.citation: N Engl J Med. 2006 Dec 14;355(24):2542-50
references.pmid: 17167137
references.citation: J Thorac Oncol. 2010 Sep;5(9):1416-23
references.pmid: 20686429
references.citation: Oncology. 2002;63(2):105-14
references.pmid: 12239444
references.citation: Ann Oncol. 2006 May;17 Suppl 5:v33-36
references.pmid: 16807460
references.citation: J Pharmacol Exp Ther. 1999 Nov;291(2):739-48
references.pmid: 10525095
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: J Clin Oncol. 2011 Mar 10;29(8):1067-74
references.pmid: 21282537
references.citation: Cancer Res. 1997 Nov 1;57(21):4838-48
references.pmid: 9354447
references.citation: Oncology (Williston Park). 2003 Apr;17(4):457-64, 469-71; discussion 471, 478-80, 483-4
references.pmid: 12735143
references.citation: Oncologist. 2009 Feb;14(2):137-47
references.pmid: 19190239
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4743-50
references.pmid: 17909199
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2544-55
references.pmid: 15753462
references.citation: Curr Oncol. 2008 Dec;15(6):279-85
references.pmid: 19079629
references.citation: J Clin Oncol. 2008 Nov 20;26(33):5326-34
references.pmid: 18854571
references.citation: Oncologist. 2009 Mar;14(3):253-63
references.pmid: 19221167
references.citation: Nat Rev Cancer. 2003 Jun;3(6):401-10
references.pmid: 12778130
references.citation: J Clin Oncol. 2006 Aug 20;24(24):3831-7
references.pmid: 16921034
references.citation: J Clin Oncol. 2009 Feb 1;27(4):591-8
references.pmid: 19075278
references.citation: Lancet. 2008 Nov 22;372(9652):1809-18
references.pmid: 19027483
references.citation: J Clin Oncol. 2004 May 1;22(9):1589-97
references.pmid: 15117980
references.citation: J Thorac Oncol. 2007 Sep;2(9):845-53
references.pmid: 17805063
references.citation: Lancet. 2009 May 2;373(9674):1525-31
references.pmid: 19410716
references.citation: Expert Opin Ther Targets. 2007 Feb;11(2):245-57
references.pmid: 17227238